C4 Therapeutics, Inc. Revenue
C4 Therapeutics, Inc. (CCCC) reported Revenue of $6.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $6.64M, a 2.75% increase year-over-year.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $6.15M, a 15.00% decline year-over-year.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $11.02M, a 112.79% increase year-over-year.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $11.23M, a 26.90% decline year-over-year.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $35.95M, a 1.02% increase from fiscal 2024.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $35.58M, a 71.44% increase from fiscal 2023.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $20.76M, a 33.25% decline from fiscal 2022.
- C4 Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $31.10M, a 32.08% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.64M 10-Q · filed 2026-08-11 | $12.79M 10-Q · filed 2026-08-11 | $23.81M derived: sum of 3 quarters · filed 2026-08-11 | $35.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $6.15M 10-Q · filed 2026-05-12 | $17.17M derived: sum of 2 quarters · filed 2026-05-12 | $28.40M derived: sum of 3 quarters · filed 2026-05-12 | $34.86M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.25M derived: sum of 2 quarters · filed 2026-02-26 | $28.71M derived: sum of 3 quarters · filed 2026-08-11 | $35.95M 10-K · filed 2026-02-26 |
| 2025-09-30 | $11.23M 10-Q · filed 2025-11-06 | $17.69M derived: sum of 2 quarters · filed 2026-08-11 | $24.93M 10-Q · filed 2025-11-06 | $30.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $6.46M 10-Q · filed 2026-08-11 | $13.70M 10-Q · filed 2026-08-11 | $18.88M derived: sum of 3 quarters · filed 2026-08-11 | $34.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.24M 10-Q · filed 2026-05-12 | $12.41M derived: sum of 2 quarters · filed 2026-05-12 | $27.78M derived: sum of 3 quarters · filed 2026-05-12 | $39.78M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $5.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.54M derived: sum of 2 quarters · filed 2026-02-26 | $32.55M derived: sum of 3 quarters · filed 2026-02-26 | $35.58M 10-K · filed 2026-02-26 |
| 2024-09-30 | $15.36M 10-Q · filed 2025-11-06 | $27.37M derived: sum of 2 quarters · filed 2025-11-06 | $30.41M 10-Q · filed 2025-11-06 | $33.67M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.01M 10-Q · filed 2025-08-07 | $15.04M 10-Q · filed 2025-08-07 | $18.31M derived: sum of 3 quarters · filed 2025-08-07 | $29.38M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $3.04M 10-Q · filed 2025-05-07 | $6.30M derived: sum of 2 quarters · filed 2025-05-07 | $17.37M derived: sum of 3 quarters · filed 2025-05-07 | $20.04M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $14.33M derived: sum of 2 quarters · filed 2025-02-27 | $17.00M derived: sum of 3 quarters · filed 2025-02-27 | $20.76M 10-K · filed 2025-02-27 |
| 2023-09-30 | $11.07M 10-Q · filed 2024-10-31 | $13.74M derived: sum of 2 quarters · filed 2024-10-31 | $17.50M 10-Q · filed 2024-10-31 | $20.35M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $2.66M 10-Q · filed 2024-08-01 | $6.42M 10-Q · filed 2024-08-01 | $9.28M derived: sum of 3 quarters · filed 2024-08-01 | $16.03M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $3.76M 10-Q · filed 2024-05-08 | $6.61M derived: sum of 2 quarters · filed 2024-05-08 | $13.37M derived: sum of 3 quarters · filed 2024-05-08 | $27.20M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $9.61M derived: sum of 2 quarters · filed 2024-02-22 | $23.44M derived: sum of 3 quarters · filed 2024-02-22 | $31.10M 10-K · filed 2024-02-22 |
| 2022-09-30 | $6.75M 10-Q · filed 2023-11-01 | $20.59M derived: sum of 2 quarters · filed 2023-11-01 | $28.24M 10-Q · filed 2023-11-01 | $48.32M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $13.83M 10-Q · filed 2023-08-08 | $21.49M 10-Q · filed 2023-08-08 | $41.57M derived: sum of 3 quarters · filed 2023-08-08 | $50.07M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $7.65M 10-Q · filed 2023-05-04 | $27.73M derived: sum of 2 quarters · filed 2023-05-04 | $36.23M derived: sum of 3 quarters · filed 2023-05-04 | $46.01M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $20.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $28.58M derived: sum of 2 quarters · filed 2023-02-23 | $38.36M derived: sum of 3 quarters · filed 2023-02-23 | $45.78M 10-K · filed 2023-02-23 |
| 2021-09-30 | $8.50M 10-Q · filed 2022-11-03 | $18.28M derived: sum of 2 quarters · filed 2022-11-03 | $25.71M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $9.78M 10-Q · filed 2022-08-04 | $17.21M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |